Posted on Leave a comment

FDA Again Urges Caution and Advises Against Using Morcellators for Uterine Fibroids

Posted on Leave a comment

Maurie Markman, MD

Hello. I am Dr Maurie Markman from Cancer Treatment Centers of America in Philadelphia, Pennsylvania.

I wanted to briefly highlight the recently updated US Food and Drug Administration (FDA) assessment on the use of laparoscopic power morcellators to treat uterine fibroids. This is clearly a complex and controversial topic, and one that has received a lot of attention in the medical and lay literature.

In December 2017, the FDA reassessed their own evaluation of the risk for the possibility of uterine sarcoma being found in fibroids and affirmed their previous findings. They noted that the risk for uterine sarcoma in women undergoing surgery for presumed fibroids ranged from approximately 1 in 225 to 1 in 580; with leiomyosarcoma specifically, the risk ranged from 1 in 495 to 1 in 1100. The FDA noted that others have reached the conclusion that the risk for sarcomas in uterine fibroids is substantially lower than this.

This reassessment looked at a number of papers in the literature and noted this level of risk, and the FDA has stated that it continues to caution against the use of laparoscopic power morcellators in the majority of women undergoing myomectomy or hysterectomy for the treatment of fibroids. Clearly, some individuals, after a very appropriate informed consent and discussion about potential medical risks associated with surgery, would elect to have this procedure performed, with the advice of their own surgeons. The FDA’s comments, based upon their data, advise great caution.

Ongoing research in this area is looking for potentially safer ways to perform morcellation so that the risk for any type of spread of material containing sarcoma can be substantially reduced, but that topic remains for the future and future publications. This review by the FDA is important for oncologists, general physicians, obstetricians, and gynecologists. We are seeing women considered for fibroid surgery, and the FDA’s review, which appears to me to be quite thoughtful, needs to be seriously considered.

Thank you for your attention. I encourage you, if you have an interest in the topic, to review the FDA’s updated assessment of the use of laparoscopic power morcellators.

– GDMeds, an India Pharmacy Service company

 

 

 

 

 

 

 

 

  • [Disclaimer]The Site is operated by GDMeds and all rights thereto are owned and reserved by GDMeds. The contents and works on these pages compiled by GDMeds are subject to copyright law. Copying, processing, distribution and any kind of use outside the limits of copyright law require the written consent of GDMeds In case the content is not created by GDMeds the copyrights of third parties are being observed. However, if a user becomes aware of a copyright infringement, GDMeds asks the user for notification. Upon notification of such violations, GDMeds will remove the content immediately.
  • [免责声明]本网站由印度极得美运营。印度极得美拥有和保留一切权利。印度极得美的网页内容及文档受版权法保护。复制、加工、传播及任何超出版权法限制的任何使用行为均必须得到印度极得美书面许可。如相关内容如非由印度极得美创作,需遵守第三方的版权,特别是标示为第三方内容的。如用户发现侵犯版权的行为,请通知极得美。一旦收到违反通知,极得美将立刻移除相关内容。
  • [отказ]Сайт управляется GDMeds, и все права на него принадлежат и зарезервированы GDMeds. Содержание и работы на этих страницах, составленные GDMeds, защищены законом об авторском праве. Копирование, обработка, распространение и любое использование вне пределов авторского права требуют письменного согласия GDMeds. Если контент не создан GDMeds, то соблюдаются авторские права третьих лиц. Однако, если пользователь узнает о нарушении авторских прав, GDMeds запрашивает у пользователя уведомление. После уведомления о таких нарушениях GDMeds немедленно удалит контент.
Leave a Reply

Your email address will not be published. Required fields are marked *